Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...

Eisai and Biogen update on lecanemab's EU regulatory ... The company routinely posts information that may be important to investors on its website at This news release contains forward-looking ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

The Alzheimer’s Association advised against diagnosing the disease on biomarkers alone, but other experts said the genie ...

Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

"Medidata is at the forefront of a critical shift in the life sciences sector," said Anthony Costello, CEO, Medidata. "By harnessing AI-powered solutions and partnering with visionaries, we aren't ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...

With the overall stock market very overbought, the four highest-yielding Dogs of the Dow look like outstanding ideas now.

Alzheimer’s Therapeutics MarketThe global Alzheimer’s therapeutics market is projected to experience significant growth, with an expected valuation of USD 3,052.3 million in 2023. The market is ...